DDMODEL00000115
|
Russu_2009_dose_escalation_power
|
PharmML 0.8.x |
Paolo Magni |
2015/12/12 |
2016/10/13 |
|
DDMODEL00000227
|
Glucose kinetics in humans: a unique model for different tests
|
PharmML 0.8.x |
Roberto Bizzotto |
2016/10/14 |
2017/06/30 |
|
DDMODEL00000005
|
Lledo-Garcia_2013_diabetes
|
PharmML 0.8.x |
Paolo Magni |
2014/09/25 |
2016/10/10 |
|
DDMODEL00000111
|
Magni_2004_diabetes_IVGTT
|
PharmML 0.8.x |
Paolo Magni |
2015/12/11 |
2017/11/08 |
|
DDMODEL00000120
|
Hansson_2013_hypertension_sunitinib
|
PharmML 0.8.x |
Paolo Magni |
2015/12/12 |
2016/10/10 |
|
DDMODEL00000233
|
Zierhut_2008_Population PKPD model for Fc-osteoprotegerin in healthy postmenopausal women
|
PharmML 0.8.x |
Kyle Baron |
2016/11/18 |
2018/07/13 |
|
DDMODEL00000116
|
Friedrich_2014_HDL
|
PharmML 0.8.x |
Paolo Magni |
2015/12/12 |
2016/10/13 |
|
DDMODEL00000006
|
Simeoni_2004_oncology_TGI
|
PharmML 0.8.x |
Paolo Magni |
2014/09/25 |
2016/10/05 |
|
DDMODEL00000112
|
Magni_2006_diabetes_MinimalModel
|
PharmML 0.8.x |
Paolo Magni |
2015/12/11 |
2016/10/13 |
|
DDMODEL00000121
|
Nathan_2008_HbA1c_prediction
|
PharmML 0.8.x |
Paolo Magni |
2015/12/12 |
2016/10/10 |
|
DDMODEL00000117
|
Friedrich_2014_LDL
|
PharmML 0.8.x |
Paolo Magni |
2015/12/12 |
2016/10/13 |
|
DDMODEL00000007
|
DelBene_2009_oncology_in_vitro
|
PharmML 0.8.x |
Paolo Magni |
2014/09/25 |
2016/10/10 |
|
DDMODEL00000122
|
Samtani_2010_Hb1Ac_prediction
|
PharmML 0.8.x |
Paolo Magni |
2015/12/12 |
2016/10/10 |
|
DDMODEL00000113
|
Russu_2009_dose_escalation_loglog
|
PharmML 0.8.x |
Paolo Magni |
2015/12/12 |
2016/10/13 |
|
DDMODEL00000003
|
Hamren_2008_diabetes_tesaglitazar
|
PharmML 0.8.x |
Paolo Magni |
2014/09/25 |
2016/10/10 |
|
DDMODEL00000118
|
Friedrich_2014_PK
|
PharmML 0.8.x |
Paolo Magni |
2015/12/12 |
2016/10/13 |
|
DDMODEL00000096
|
Terranova_2013_oncology_TGI_combo
|
PharmML 0.8.x |
Paolo Magni |
2015/12/10 |
2016/10/10 |
|
DDMODEL00000008
|
Rocchetti_2013_oncology_TGI_combo
|
PharmML 0.8.x |
Paolo Magni |
2014/09/26 |
2016/10/10 |
|
DDMODEL00000123
|
AitOudhia_2012_CRP_canakinumab
|
PharmML 0.8.x |
Paolo Magni |
2015/12/12 |
2016/10/13 |
|
DDMODEL00000274
|
Terranova_2017_oncology_TGI
|
PharmML 0.8.x |
Elena Maria Tosca |
2017/12/21 |
2017/12/22 |
|
DDMODEL00000114
|
Russu_2009_dose_escalation_Emax
|
PharmML 0.8.x |
Paolo Magni |
2015/12/12 |
2016/10/13 |
|
DDMODEL00000004
|
DeWinter_2006_diabetes
|
PharmML 0.8.x |
Paolo Magni |
2014/09/25 |
2016/10/10 |
|
DDMODEL00000110
|
Magni_2000_diabetes_C-peptide
|
PharmML 0.8.x |
Paolo Magni |
2015/12/11 |
2017/11/08 |
|
DDMODEL00000119
|
Bender_2012_thrombocytopenia_TDM1
|
PharmML 0.8.x |
Paolo Magni |
2015/12/12 |
2016/10/13 |
|
DDMODEL00000124
|
Madrasi_2014_HIV_tenofovir
|
PharmML 0.8.x |
Paolo Magni |
2015/12/13 |
2016/10/10 |
|
DDMODEL00000101
|
Overgaard’s beta cell model for insulin secretion
|
PharmML |
Roberto Bizzotto |
2015/12/11 |
2016/09/20 |
|
DDMODEL00000087
|
Benson 2014 - FAAH Inhibitors Systems Pharmacology Model for Pain
|
PharmML |
Phylinda Chan |
2015/12/10 |
2016/05/25 |
|
DDMODEL00000212
|
TerHeine_2014_PK_Tamoxifen_ActiveMetabolite_CYP2D6
|
PharmML |
Lena Klopp-Schulze |
2016/08/26 |
2016/08/30 |
|
DDMODEL00000107
|
Girard_2013_oncology_cetuximab_TGI
|
PharmML |
Nadia Terranova |
2015/12/11 |
2016/07/22 |
|
DDMODEL00000001
|
Friberg_2009_Schizophrenia_Prolactin
|
PharmML |
Zinnia Parra-Guillen |
2014/09/24 |
2016/05/24 |
|
DDMODEL00000131
|
Dose-response characteristics of insulin action on glucose metabolism
|
PharmML |
Roberto Bizzotto |
2015/12/29 |
2016/05/18 |
|
DDMODEL00000102
|
Meibohm_2013_oncology_EMD525797_TMDD
|
PharmML |
Nadia Terranova |
2015/12/11 |
2016/07/18 |
|
DDMODEL00000089
|
Chan 2010 - HIV PKPD Viral Load Model
|
PharmML |
Phylinda Chan |
2015/12/10 |
2016/05/25 |
|
DDMODEL00000213
|
Li_2006_PK_Meropenem_AdultPatients
|
PharmML |
Lisa Ehmann |
2016/08/26 |
2016/08/30 |
|
DDMODEL00000108
|
Chen’s exocytosis model
|
PharmML |
Roberto Bizzotto |
2015/12/11 |
2016/05/18 |
|
DDMODEL00000127
|
Bueno_PreclinicalBiomarkerTGI
|
PharmML |
Niklas Hartung |
2015/12/14 |
2016/07/15 |
|
DDMODEL00000002
|
Friberg_2009_Schizophrenia_Asenapine_PANSS
|
PharmML |
Zinnia Parra-Guillen |
2014/09/24 |
2016/05/18 |
|
DDMODEL00000094
|
Insulin sensitivity from labeled IVGTT
|
PharmML |
Roberto Bizzotto |
2015/12/10 |
2016/05/18 |
|
DDMODEL00000229
|
A model for monoclonal antibody-based targeted therapy of Gemtuzumab Ozogamicin (GO) for acute myeloid leukemia (AML)
|
PharmML |
Moran Optimata |
2016/10/26 |
2016/11/01 |
|
DDMODEL00000195
|
Sibrotuzumab_PK_Carcinoma
|
PharmML |
Niklas Hartung |
2016/05/31 |
2016/07/15 |
|
DDMODEL00000132
|
Minimal model
|
PharmML |
Roberto Bizzotto |
2015/12/29 |
2016/05/18 |
|
DDMODEL00000103
|
Trefz_2015_metabolism_Kuvan_TurnoverKPD
|
PharmML |
Nadia Terranova |
2015/12/11 |
2016/07/18 |
|
DDMODEL00000090
|
Claret_2009_oncology_capecitabine_TGI
|
PharmML |
Nadia Terranova |
2015/12/10 |
2016/07/13 |
|
DDMODEL00000128
|
Ribba_2012_PCV
|
PharmML |
Christian Laveille |
2015/12/15 |
2015/12/16 |
|
DDMODEL00000230
|
A pharmacokinetic model for interleukin-21 therapy validated prospectively in murine experiments in melanoma
|
PharmML |
Moran Optimata |
2016/10/26 |
2016/11/01 |
|
DDMODEL00000078
|
Chalret_2014_Abexinostat
|
PharmML |
Vincent Croixmarie |
2015/12/09 |
2016/02/12 |
|
DDMODEL00000091
|
Van Cauter C-peptide model
|
PharmML |
Roberto Bizzotto |
2015/12/10 |
2016/05/18 |
|
DDMODEL00000186
|
Friberg_2002_Oncology_Paclitaxel_Myelosuppression
|
PharmML |
Zinnia Parra-Guillen |
2016/05/17 |
2016/08/24 |
|
DDMODEL00000225
|
PKPD model for ciprofloxacin
|
PharmML |
David Khan |
2016/10/13 |
2016/10/13 |
|
DDMODEL00000129
|
Peigne_2015_Ivabradine
|
PharmML |
Vincent Croixmarie |
2015/12/16 |
2016/02/12 |
|